Anthem Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 09-12-2024
- Paid Up Capital ₹ 1.93 M
as on 09-12-2024
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 Cr
as on 09-12-2024
- Satisfied Charges ₹ 2.00 Cr
as on 09-12-2024
- Revenue 30.93%
(FY 2023)
- Profit -473.33%
(FY 2023)
- Ebitda -45.42%
(FY 2023)
- Net Worth -8.81%
(FY 2023)
- Total Assets 26.16%
(FY 2023)
About Anthem Bio Pharma
The Corporate was formerly known as Vestas Life Sciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.93 M.
The company currently has active open charges totaling ₹7.50 Cr. The company has closed loans amounting to ₹2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ajay Bhardwaj and Malay Jiban serve as directors at the Company.
- CIN/LLPIN
U24232KA2009PTC051551
- Company No.
051551
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Nov 2009
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore Rural, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Anthem Bio Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Bhardwaj  | Director | 04-Feb-2011 | Current |
| Malay Jiban | Director | 17-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Anthem Bio Pharma.
Anthem Bio Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 30.93% increase. The company also saw a substantial fall in profitability, with a 473.33% decrease in profit. The company's net worth dipped by a decrease of 8.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anthem Bio Pharma?
In 2023, Anthem Bio Pharma had a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Feb 2019 | ₹7.50 Cr | Open |
State Bank Of India Creation Date: 28 Jul 2011 | ₹2.00 Cr | Satisfied |
How Many Employees Work at Anthem Bio Pharma?
Anthem Bio Pharma has a workforce of 173 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anthem Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anthem Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
